Anti-Human FOLH1/PSMA Reference Antibody (MEDI3726, RUO)

Catalog No.	HC669086
Brand	abinScience
Host species	Human
Species reactivity	Human
Form	Liquid
Storage buffer	0.01M PBS pH 7.4
Purity	>95% purity as determined by SDS-PAGE.
Clonality	Monoclonal
Isotype	IgG
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Target	NAALAD1, Prostate-specific membrane antigen, NAALADase I, PSMA, PSM, Pteroylpoly-gamma-glutamate carboxypeptidase, Glutamate carboxypeptidase 2, N-acetylated-alpha-linked acidic dipeptidase I, Glutamate carboxypeptidase II, FOLH1, FGCP, FOLH, Folylpoly-gamma-glutamate carboxypeptidase, Folate hydrolase 1, GCPII, Membrane glutamate carboxypeptidase, Cell growth-inhibiting gene 27 protein, mGCP
References	1. de Bono JS, et al. Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide. Clin Cancer Res. 2021;27(13):3602-3609. [HC669086] 2. Huang Y, et al. Multifaceted Bioanalytical Methods for the Comprehensive Pharmacokinetic and Catabolic Assessment of MEDI3726, an Anti-Prostate-Specific Membrane Antigen Pyrrolobenzodiazepine Antibody-Drug Conjugate. Anal Chem. 2020;92(16):11135-11144. [HC669086] 3. Francesca Zammarchi, et al. ADCT-401/MEDI3726, a novel pyrrolobenzodiazepine (PBD)-based antibody-drug conjugate (ADC) targeting PSMA-expressing prostate cancers. Cancer Res 2017;77(13 Suppl):Abstract nr 3111A. [HC669086] 4. Cho S, et al. Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer. Mol Cancer Ther. 2018;17(10):2176-2186. View More [HC669086]
Purification	Protein A/G purified from cell culture supernatant.
Biological activity	MEDI3726 (ADCT-401) exhibits potent, specific cytotoxicity in PSMA-expressing prostate cancer cell lines, with greatly reduced activity in PSMA-negative prostate cancer cell lines [3]. MEDI3726 (0.2 ug/mL; 1 h) cross-reacts with human and cynomolgus monkey soluble PSMA with similar potency, but does not cross-react with rat soluble PSMA [4]. MEDI3726 (up to 7 days) remains stable and active at 37°C in PBS, human plasma, or cynomolgus monkey plasma [4]. MEDI3726 (5-7 days) potently and specifically kills PSMA-positive human prostate cancer cell lines LNCaP (IC 50 = 0.02 nM), LNCaP C4-2 (IC 50 = 0.06 nM), MDA PCa 2b (IC 50 = 0.002 nM), and CWR22Rv1 (IC 50 = 0.29 nM), but shows no targeted cytotoxicity in PSMA-negative PC-3 (IC 50 = 29.3 nM) and DU145 cell lines (IC 50 = 44.9 nM) [4]. MEDI3726 (24 h) is specifically internalized and trafficked to lysosomes in PSMA-positive LNCaP cells, but not in PSMA-negative PC-3 cells [4]. MEDI3726 (6 nM; 2 h treatment) induces persistent DNA interstrand crosslinks in PSMA-positive LNCaP cells, but does not induce significant DNA crosslinking in PSMA-negative PC-3 cells [4]. catabolism primarily via heavy-light chain dissociation, with minimal warhead deconjugation. MEDI3726 can be used for the research of metastatic castration-resistant prostate cancer and prostate cancers [1] [2] [3] [4].
Endotoxin level	< 10 EU/mg
Expression system	Mammalian cells
Accession	Q04609
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative name	MEDI3726
Clone ID	MEDI3726
Note	For research use only. Not suitable for clinical or therapeutic use.